Skip to content

Role of Dos and Dons in the patients of Diabetes Mellitus

A STUDY OF SWABHAVOPARAM VADA (NIDANA PARIVARJANA) AND ITS OBSERVATION IN NEWLY DIAGNOSED MADHUMEHA (TYPE 2 DIABETES MELLITUS)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/06/019794
Enrollment
60
Registered
2019-06-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Phalatrikadi kwath given twice per day along with Nidana Parivarjana in the pateints of Newly Diagnosed Madhumeh (Type 2 Diabetes Mellitus) for 3 months.: Phalatrikadi Kwath 40 ml twice

Sponsors

All India Institute of Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Both Obese and non-Obese patients. Patients showing Classical signs and symptoms of Madhumeha Fasting blood sugar (FBS) >126 mg/dl or Postprandial blood sugar (PPBS) >200 mg/dl

Exclusion criteria

Exclusion criteria: Patients who are under Conventional Medications. Subjects with Juvenile Diabetes, Gestational Diabetes, IDDM Subject of Stress Induced Diabetes Excessive blood glucose: FBS >375 mg/dl and PPBS > 500 mg/dl Patients with Diabetic complications (microvascular and macrovascular). Patients with Grave Diseases, Psychological disorders.

Design outcomes

Primary

MeasureTime frame
Improvement in the Cardinal Sign & Symptoms of Madhumeha. Glycosylated haemoglobin (in %) â?? to be assessed at the beginning and at the end of the trial FBS 126 mg/dl PPBS 200 mg/dlTimepoint: 3 Months

Secondary

MeasureTime frame
To improve the Quality of LifeTimepoint: 3 months

Countries

India

Contacts

Public ContactPratigya Chauhan

All India Institute of Ayurveda

drmaheshkvyas@gmail.com9426953118

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026